Plasma cell myeloma
RecruitingA study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant
A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant
- Disease:Plasma cell myeloma
- Substances:DaratumumabDexamethasone+2
France- Participants:18–64 years · 65+ years
- Substances:Daratumumab
- Sponsor:AbbVie Deutschland GmbH & Co. KG












